An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...